A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...

Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SGLT2 inhibitors and GLP-1 receptor agonists were associated with fewer exacerbations of COPD in adults with type 2 ...

Age differences are seen in the efficacy of treatments for type 2 diabetes, according to a study published online Feb ...

Swimsuit Illustrated Sports Issue model and Denise Austin's daughter, Katie Austin, explained why she will never take Ozempic.

As drugs like Ozempic and Mounjaro continue to skyrocket in usage, doctors are encountering more cases linking them to ...

Groundbreaking research reveals how common diabetes medications might offer unprecedented protection against heart attacks ...

The results of this comparative effectiveness research study suggest that sodium-glucose cotransporter-2 inhibitors  and glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a ...

The global Diabetes Drugs Market size was valued at USD 84.65 billion in 2024 and is expected to be worth around USD 177.74 ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

The following is a summary of “Effects of Novel Antidiabetic Agents on Contrast-Associated Acute Kidney Injury in Diabetic Patients Undergoing Percutaneous Coronary Intervention,” published in the ...